MYCN and cancer: Nonetheless, MYCN-driven cancer cells treated with PARP inhibitors enter mitosis with damaged DNA and undergo mitotic catastrophe, suggesting that increasing oncogene-dependent RS is another mechanism contributing to lethality by PARP inhibitors [38].